HK1209453A1 - Methods of generating mesenchymal stem cells which secrete neurotrophic factors - Google Patents
Methods of generating mesenchymal stem cells which secrete neurotrophic factorsInfo
- Publication number
- HK1209453A1 HK1209453A1 HK15109965.5A HK15109965A HK1209453A1 HK 1209453 A1 HK1209453 A1 HK 1209453A1 HK 15109965 A HK15109965 A HK 15109965A HK 1209453 A1 HK1209453 A1 HK 1209453A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- stem cells
- mesenchymal stem
- neurotrophic factors
- secrete neurotrophic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/195—Heregulin, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70585—CD44
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261679822P | 2012-08-06 | 2012-08-06 | |
PCT/IL2013/050660 WO2014024183A1 (en) | 2012-08-06 | 2013-08-04 | Methods of generating mesenchymal stem cells which secrete neurotrophic factors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1209453A1 true HK1209453A1 (en) | 2016-04-01 |
Family
ID=49253370
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15109965.5A HK1209453A1 (en) | 2012-08-06 | 2015-10-13 | Methods of generating mesenchymal stem cells which secrete neurotrophic factors |
Country Status (10)
Country | Link |
---|---|
US (3) | US10046010B2 (da) |
EP (1) | EP2880151B1 (da) |
JP (2) | JP6362596B2 (da) |
BR (1) | BR112015001435B1 (da) |
CA (1) | CA2877223C (da) |
DK (1) | DK2880151T3 (da) |
ES (1) | ES2813407T3 (da) |
HK (1) | HK1209453A1 (da) |
IL (1) | IL261441B (da) |
WO (1) | WO2014024183A1 (da) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2813407T3 (es) | 2012-08-06 | 2021-03-23 | Brainstorm Cell Therapeutics Ltd | Métodos para generar células madre mesenquimales que secretan factores neurotróficos |
TWI637951B (zh) | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
JP6628253B2 (ja) | 2014-02-11 | 2020-01-08 | ブレインストーム セル セラペウティクス リミテッド | 細胞の適性を判定する方法 |
CN107208049A (zh) * | 2014-09-18 | 2017-09-26 | 财团法人卫生研究院 | 祖细胞、其制备方法及其应用 |
PL3286300T3 (pl) | 2015-04-24 | 2021-05-04 | University Of Copenhagen | Izolacja bona fide komórek progenitorowych trzustki |
CN105169486B (zh) * | 2015-10-11 | 2018-04-03 | 温州医科大学 | 一种结合去细胞神经应用的神经修复材料 |
GB2605113A (en) * | 2016-05-09 | 2022-09-21 | Sistemic Scotland Ltd | Functional prediction |
SG11201809902QA (en) | 2016-05-09 | 2018-12-28 | Sistemic Scotland Ltd | Functional prediction of cellular functions by means of microrna expression profiling in mesenchymal stem cells |
GB2550136A (en) * | 2016-05-09 | 2017-11-15 | Sistemic Scotland Ltd | Functional prediction |
US20210128627A1 (en) | 2016-07-18 | 2021-05-06 | Brainstorm Cell Therapeutics Ltd. | Methods for treating amyotrophic lateral sclerosis (als) |
CN110050063B (zh) * | 2016-09-12 | 2023-11-03 | 吉尼松公司 | 酸性α-葡萄糖苷酶变体及其用途 |
MX2019005127A (es) | 2016-11-03 | 2019-09-26 | Exostem Biotec Ltd | Poblaciones y productos de células madre mesenquimales y sus usos. |
WO2018198012A1 (en) * | 2017-04-24 | 2018-11-01 | Pluristem Ltd. | Methods and compositions for treating neurological disorders |
US20190054144A1 (en) * | 2017-08-15 | 2019-02-21 | Meridigen Biotech Co., Ltd. | Pharmaceutical composition for treating ischemic stroke and method thereof |
US11286462B2 (en) | 2017-09-14 | 2022-03-29 | University Of Kansas | Materials and methods for generating therapeutic mesenchymal stem cells |
CN111093680A (zh) * | 2017-09-15 | 2020-05-01 | 洋蓟治疗有限公司 | 治疗变应性气道疾病(aad)/哮喘的方法 |
CA2983845C (en) | 2017-10-26 | 2024-01-30 | University Of Copenhagen | Generation of glucose-responsive beta cells |
IL277447B2 (en) * | 2018-04-10 | 2024-04-01 | Brainstorm Cell Therapeutics Ltd | Cell-adapted exosomes and their uses |
US20200000886A1 (en) * | 2018-06-29 | 2020-01-02 | University Of Washington | Engineering the rrm2 subunit of ribonucleotide reductase to resist degradation |
CN111484978A (zh) * | 2019-01-28 | 2020-08-04 | 深圳市第二人民医院 | miR-140-5p过表达修饰的人脐带间充质干细胞、其治疗制剂、制备方法和应用 |
AU2020236160A1 (en) | 2019-03-14 | 2021-09-16 | Nipro Corporation | Pharmaceutical composition for treating amyotrophic lateral sclerosis |
KR102323056B1 (ko) * | 2019-05-02 | 2021-11-09 | 에스씨엠생명과학 주식회사 | hPL 함유 배지에서 배양된 중간엽 줄기세포의 배양액을 포함하는 화장료 조성물 |
EP3985104A4 (en) * | 2019-06-11 | 2023-04-12 | Kyoto University | PROCEDURE FOR GENERATING A KIDNEY INTERSTITIAL CELL |
WO2021183674A1 (en) * | 2020-03-11 | 2021-09-16 | Remotor Therapeutics, Inc. | Methods and materials for disseminating a protein throughout the central nervous system |
KR20230128452A (ko) * | 2020-10-26 | 2023-09-05 | 하다지트 메디칼 리서치 써비시즈 앤드 디벨롭먼트 리미티드 | 중간엽 줄기 세포 및 이의 배양 |
WO2022210514A1 (ja) | 2021-03-30 | 2022-10-06 | 株式会社カネカ | トリプシン阻害方法、それを用いた細胞製剤の製造方法 |
CN113367123B (zh) * | 2021-06-07 | 2022-05-13 | 南京三生生物技术股份有限公司 | 一种细胞冻存方法 |
CN113789333B (zh) * | 2021-09-07 | 2023-07-14 | 中国人民解放军军事科学院军事医学研究院 | Chi3l1在调控hUC-MSCs抑制Th17分化介导的免疫调节作用上的应用 |
WO2023219655A1 (en) * | 2022-05-13 | 2023-11-16 | University Of Utah Research Foundation | Gja1-20k to limited cardiac arrhythmias |
CN116410921B (zh) * | 2023-02-09 | 2024-01-23 | 北京益华生物科技有限公司 | 一种人源脐带间充质干细胞诱导培养基、诱导方法及应用 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5004681B1 (en) | 1987-11-12 | 2000-04-11 | Biocyte Corp | Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood |
US5192553A (en) | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
EP0668013B1 (en) | 1994-02-22 | 2005-04-20 | Nippon Telegraph And Telephone Corporation | Freeze-dried blood cells, stem cells and platelets and manufacturing method for the same |
US5955257A (en) | 1997-10-21 | 1999-09-21 | Regents Of The University Of Minnesota | Infusible grade short-term cell storage medium for mononuclear cells |
JP3948971B2 (ja) * | 2001-08-30 | 2007-07-25 | サンバイオ,インコーポレイティド | Notch遺伝子の導入を用いて骨髄間質細胞を神経細胞及び骨格筋細胞に分化・誘導する方法 |
EP2270146A1 (en) | 2002-02-06 | 2011-01-05 | Sanbio, Inc. | Method of inducing differentiation of bone marrow stromal cells to neural cells or skeletal muscle cells by introduction of notch gene |
US20030215942A1 (en) | 2002-02-14 | 2003-11-20 | Stemcyte, Inc. | Undesignated allogeneic stem cell bank |
IL152905A0 (en) | 2002-11-17 | 2003-06-24 | Univ Ramot | Dopaminergic markers induction in neuronal-like cells isolated from adult human bone marrow stromal cells: implications for novel gene therapy strategy for parkinsons disease |
US20050265983A1 (en) | 2002-11-17 | 2005-12-01 | Eldad Melamed | Methods, nucleic acid constructs and cells for treating neurodegenerative disorders |
DK1893747T3 (da) * | 2005-06-16 | 2014-12-01 | Univ Ramot | Isolerede celler og populationer, der omfatter sådanne celler, til behandling af cns-sygdomme |
US20100021434A1 (en) | 2005-12-08 | 2010-01-28 | Ramot At Tel Aviv University Ltd. | Isolated Oligodendrocyte-Like Cells and Populations Comprising Same for the Treatment of CNS Diseases |
ES2729557T3 (es) * | 2008-05-28 | 2019-11-04 | Univ Ramot | Células madre mesenquimatosas para el tratamiento de enfermedades del SNC |
US20100184033A1 (en) | 2008-07-16 | 2010-07-22 | West Michael D | Methods to accelerate the isolation of novel cell strains from pluripotent stem cells and cells obtained thereby |
KR102073730B1 (ko) | 2009-11-17 | 2020-02-05 | 아스텔라스 인스티튜트 포 리제너러티브 메디슨 | 인간 rpe 세포의 생산 방법 및 인간 rpe 세포의 제약 제제 |
DE102011121982B3 (de) | 2011-12-22 | 2013-04-18 | Dietmar Hopp Stiftung GmbH | Mesenchymale Stammzellen aus Fettgewebe (ADSC) zur Rekonstruktion von Haut und Weichteilgewebe |
ES2813407T3 (es) | 2012-08-06 | 2021-03-23 | Brainstorm Cell Therapeutics Ltd | Métodos para generar células madre mesenquimales que secretan factores neurotróficos |
JP6628253B2 (ja) | 2014-02-11 | 2020-01-08 | ブレインストーム セル セラペウティクス リミテッド | 細胞の適性を判定する方法 |
-
2013
- 2013-08-04 ES ES13767124T patent/ES2813407T3/es active Active
- 2013-08-04 EP EP13767124.4A patent/EP2880151B1/en active Active
- 2013-08-04 JP JP2015526006A patent/JP6362596B2/ja active Active
- 2013-08-04 CA CA2877223A patent/CA2877223C/en active Active
- 2013-08-04 BR BR112015001435-6A patent/BR112015001435B1/pt active IP Right Grant
- 2013-08-04 DK DK13767124.4T patent/DK2880151T3/da active
- 2013-08-04 US US14/419,668 patent/US10046010B2/en active Active
- 2013-08-04 WO PCT/IL2013/050660 patent/WO2014024183A1/en active Application Filing
-
2015
- 2015-10-13 HK HK15109965.5A patent/HK1209453A1/xx unknown
-
2018
- 2018-04-20 JP JP2018081151A patent/JP6753887B2/ja active Active
- 2018-06-27 US US16/019,565 patent/US20180296607A1/en not_active Abandoned
- 2018-08-29 IL IL26144118A patent/IL261441B/en active IP Right Grant
-
2021
- 2021-07-14 US US17/375,032 patent/US20210338739A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL261441A (en) | 2018-10-31 |
US10046010B2 (en) | 2018-08-14 |
DK2880151T3 (da) | 2020-08-17 |
IL261441B (en) | 2019-10-31 |
WO2014024183A1 (en) | 2014-02-13 |
CA2877223A1 (en) | 2014-02-13 |
JP6362596B2 (ja) | 2018-07-25 |
BR112015001435B1 (pt) | 2022-01-18 |
EP2880151A1 (en) | 2015-06-10 |
CA2877223C (en) | 2019-08-27 |
JP2018138044A (ja) | 2018-09-06 |
US20180296607A1 (en) | 2018-10-18 |
JP6753887B2 (ja) | 2020-09-09 |
BR112015001435A2 (pt) | 2018-07-31 |
US20210338739A1 (en) | 2021-11-04 |
US20150209389A1 (en) | 2015-07-30 |
JP2015531594A (ja) | 2015-11-05 |
ES2813407T3 (es) | 2021-03-23 |
EP2880151B1 (en) | 2020-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261441A (en) | Methods for the formation of mesenchymal stem cells that secrete neurotrophic factors | |
HK1199905A1 (en) | Culturing of mesenchymal stem cells | |
SG11201407626QA (en) | Umbilical cord mesenchymal stem cell exosomes | |
EP2893001A4 (en) | METHOD OF CULTURING MESENCHYMAL STEM CELLS | |
EP2861612A4 (en) | METHODS FOR PREPARING PLURIPOTENT STEM CELLS | |
EP2847320A4 (en) | OSTEOGEN DIFFERENTIATION OF MESENCHYMAL STEM CELLS | |
EP2844738A4 (en) | GENERATION OF NOVO OF PLURIPOTENT CELLS | |
HK1222200A1 (zh) | 製備多能幹細胞的方法 | |
EP2970905A4 (en) | COMPOSITIONS AND METHODS FOR ENRICHED MESENCHYMAL STEM CELL CULTURES | |
PL2758523T3 (pl) | Zrębowe komórki macierzyste | |
EP2900808A4 (en) | METHOD FOR DIFFERENTIATING STEM CELLS IN CHONDROCYTES | |
EP2912166A4 (en) | METHOD FOR THE PRODUCTION OF PLURIPOTENTIAL STEM CELLS FROM CHONDROCYTES | |
EP3013944A4 (en) | Composition of mesenchymal stem cells | |
EP3383182C0 (en) | METHODS FOR PRODUCING FUNCTIONAL HEMATOPOIETIC STEM CELLS | |
SG11201503167XA (en) | Method of efficiently establishing induced pluripotent stem cells | |
EP2949746A4 (en) | METHOD OF SUB-CULTURE OF PLURIPOTENT STEM CELLS | |
EP3050961A4 (en) | Method for improving efficiency of inducing pluripotent stem cell | |
SG11201509767UA (en) | Medium for culturing stem cells | |
ZA201504388B (en) | Method for culturing pluripotent stem cells | |
EP2911709A4 (en) | CHONDROCYTE GRAFT METHODS | |
SG11201703600YA (en) | Method of distinguishing mesenchymal stem cells | |
IL236116A0 (en) | Methods for controlled gene expression | |
EP3015551A4 (en) | PROCESS FOR SCREENING FOR A FACTOR FOR SPREADING PLURIPOTENTAL STEM CELLS | |
HK1195100A1 (zh) | 用於人間充質幹細胞的培養基 | |
EP2946008A4 (en) | METHODS OF MOBILIZING HEMATOPOIETIC STEM CELLS |